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Abstract (word count =250) 
Objective: To determine total physician encounters, emergency room (ER) visits and 
hospitalizations in an incident cohort of systemic lupus erythematosus (SLE) cases and 
matched control patients over 13 years. 
Methods: A retrospective cohort study was performed utilizing administrative health 
care data from approximately 1 million people with access to universal healthcare. 
Using ICD-9 and ICD-10 diagnostic codes, 7 SLE case definitions were used. Each 
case was matched by age and gender to 4 randomly selected controls. Data included 
physician billings, ER visits and hospital discharges over 13 years.  
Results: The number of incident SLE cases varied from 564 to 4,494 depending up the 
case definition. The mean age varied from 47.7 to 50.6 years and the proportion of 
females from 78.0 to 85.1%. SLE utilization of physicians was highest in the index year, 
declining significantly thereafter for all case definitions. By the fourth year, encounters 
with subspecialty physicians fell by 60% (Rheumatologists), 50% (Internal medicine) 
and 31% (other physicians). In contrast, visits to family physicians fell by only 9%. Visits 
to the ER  and hospital admissions for SLE cases were also more frequent early in the 
disease and fell significantly over the study for both ER visits (all case definitions) and 
hospitalizations (2 of 7 case definitions).  
Conclusion: In SLE patients, health care utilization is highest in the first few years 
following the diagnosis which is also the time of maximal involvement by 
rheumatologists. Utilization declines over time and encounters with patient’s family 
physicians predominate over other physician groups. 
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Significance and Innovations  
 In a population health study utilizing 7 case definitions for SLE we demonstrate a 
consistently higher utilization of physician resources by SLE patients compared 
to age and gender matched controls over 13 years of observation. 
 
 Rheumatology and other subspecialty physician resources are utilized most 
intensely in the first 4 years following the diagnosis of SLE. 
 
 Emergency room visits and hospitalizations are most frequent early in the course 
of disease, falling gradually thereafter. 
Page 4 of 29
John Wiley & Sons, Inc.
Arthritis Care & Research
This article is protected by copyright. All rights reserved.
5 
 
Systemic lupus erythematosus (SLE) is one of the most frequent autoimmune 
inflammatory rheumatic diseases, characterized by its higher frequency in women and 
certain racial/ethnic groups (1). It has the potential to affect any organ system in the 
body. The clinical manifestations vary from subtle, slowly progressive symptoms such 
as fatigue, rash and arthritis to rapidly progressive and potentially life threatening 
disease due to renal or nervous system involvement. The clinical outcome for both mild 
and severe cases is improved by a prompt and accurate diagnosis, appropriate access 
to health care providers and institution of evidence based treatments. 
 
Planning for the provision of future health resources required for the diagnosis and 
treatment of SLE patients starts with an assessment of previous and current resource 
utilization.  Different research methodologies have been used to address this, including 
case-control strategies in tertiary referral centers, observational cohorts and population 
health administrative datasets. Resource utilization and associated costs have been 
examined in various geographic locations including the USA (2-7), Canada (8) and 
other countries (9-11). This is appropriate as findings are influenced by health care 
system delivery which is highly variable.  Due to the rapid pace of reform of health care 
delivery and the chronicity of SLE which extends over a patient’s lifetime, it is necessary 
to periodically update utilization in representative geographic locations. As part of an 
overall evaluation of health care resource utilization by SLE patients in our region we 
examined the total physician encounters, emergency room visits and hospitalizations in 
SLE and control patients over 13 years using a validated population health dataset. 
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Materials and Methods 
Study populations and controls: This was a retrospective cohort study of patients 
with a diagnosis of SLE within the Nova Scotia Medical Services Insurance (MSI) 
program. Nova Scotia is a Canadian province of approximately 1 million inhabitants. 
There are 3,500 physicians in Nova Scotia of which approximately 50% work in primary 
care, 7% are general internists and 0.3% are adult rheumatologists. Health care 
services including acute and elective hospitalizations and ambulatory physician visits 
are universally provided as specified under the Canada Health Act. The eligible 
population for the study of prevalent cases was Nova Scotia residents who were 
enrolled in the MSI program between April 1st 1997 and March 31st 2011. This excludes 
First Nation Canadians and members of the Canadian armed forces. Incident cases of 
SLE were defined as those without a physician billing for the same diagnosis in the 
preceding 5 years (12). Prevalent cases included both incident and non-incident cases.  
Patients with SLE were matched one to four by age and gender to a control cohort of 
patients who were also enrolled in the MSI program at the time of their matched case’s 
date of diagnosis and who never had a diagnosis of SLE or other connective tissue 
diseases.  
 
The data was obtained from existing databases accessed through the Population Health 
Research Unit (PHRU) (current title Health Data Nova Scotia (HDNS)) in the 
Department of Community Health & Epidemiology at Dalhousie University in Halifax, 
Nova Scotia, Canada. Within this unit there are secure research computing facilities on 
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site and access to data is governed by PHRU/HDNS Data Access Guidelines and 
Procedures. Electronic utilization data from the Nova Scotia Senior Pharmacare 
Program (NSSPP) for seniors (age≥65), the Canadian Institute of Health Information 
(CIHI) Hospital Discharge Abstracts database and the MSI Physician Billings database 
were linked via medical services insurance (MSI) number. The study protocol was 
reviewed and approved by the Capital Health Research Ethics Board. Informed consent 
from individual patients was not required as the study utilized secondary administrative 
data. 
 
Case definitions for identification of SLE cases and validation: The following 7 
individual case definitions, 3 of which were based upon previously published work, were 
used to identify cases of SLE in the administrative databases. We have previously 
validated these case definitions against a clinical dataset of SLE patients and controls 
(13).  The diversity of the decision rules provides a range of sensitivity and specificity for 
case ascertainment, thus permitting a degree of sensitivity analysis of health care 
utilization. 
#1 Any encounter: Any single diagnostic code for SLE by a physician. 
#2 MacLean (14): Two physician visits for SLE at least 2 months apart. 
#3 MacLean/Lacaille (12): MacLean-like algorithm with Lacaille variation (excluded 
individuals with at least 2 visits, at least 2 months apart, subsequent to the second SLE 
visit, with 2 identical diagnoses of other inflammatory arthritides and connective tissue 
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diseases (RA, psoriatic arthritis, ankylosing spondylitis, and other spondylarthropathies, 
scleroderma, Sjogren’s syndrome, dermatomyostis, polymyositis, other connective 
tissue diseases, primary systemic vasculitis) and those where a diagnosis of SLE by a 
non-rheumatologist was not confirmed if/when the individual saw a rheumatologist. 
#4 Shipton-like: Three SLE diagnostic billing codes, over any time period, rather than 
in 3 consecutive years as described by Shipton et al (15). 
#5 Hospitalization: At least one hospitalization where SLE was in the diagnostic codes.  
#6 Rheumatologist: At least one SLE code contributed by a rheumatologist. 
#7 Combination: MacLean-like algorithm (2 non-Rheumatology physician visits for SLE 
at least 2 months apart, within a 2 year period) or at least one SLE code contributed by 
a rheumatologist or at least one hospitalization where SLE was in the diagnostic codes 
and Lacaille variation, i.e. excluding individuals with at least 2 visits, at least 2 months 
apart, subsequent to the second visit, with 2 identical diagnoses of other inflammatory 
arthritides and connective tissue diseases (RA, psoriatic arthritis, ankylosing spondylitis, 
and other spondylarthropathies, scleroderma, Sjogren’s syndrome, dermatomyostis, 
polymyositis, other connective tissue diseases, primary systemic vasculitis) and 
excluding those where a diagnosis of SLE by a non-rheumatologist was not confirmed 
if/when the individual saw a rheumatologist. 
Data collection: Individual level data were obtained. Computerized claims were linked 
by encrypted health card number to the Canadian Institute of Health Information (CIHI) 
Page 8 of 29
John Wiley & Sons, Inc.
Arthritis Care & Research
This article is protected by copyright. All rights reserved.
9 
 
Hospital Discharge Abstracts and MSI Physician Billings for fiscal years from April 1st 
1997 and March 31st 2011.  
 
The following ICD-9 and ICD-10 diagnostic codes were used: 
Systemic lupus erythematosus (ICD-9: 710.0.  ICD-10: ICD-10: M 32, M32.1, M32.8, 
M32.9).   
Rheumatoid arthritis (ICD-9: 714.0, 714.1, 714.2.  ICD-10: MO5 – MO5.9, MO6.0, 
MO6.8, MO6.9).  
Psoriatic arthritis (ICD-9: 696.0.  ICD-10: L40.5) 
Ankylosing spondylitis (ICD-9: 720.0.  ICD-10: M45) 
Other spondylarthropathies (ICD-9: 720.1, 720.2, 720.8, 720.9.  ICD-10: M46.0, 
M46.1, M46.2, M46.3, M46.4, M46.5 M46.8, M46.9) 
Scleroderma (ICD-9: 710.1.  ICD-10: M34) 
Sjogren’s syndrome (ICD-9: 710.2. ICD-10: M35.0) 
Dermatomyositis (ICD-9: 710.3. ICD-10: M33.1, M33.9) 
Polymyositis (ICD-9: 710.4. ICD-10: M33.2) 
Other connective tissue diseases (ICD-9:710.5, 710.8, 710.9. ICD-10: M35.1, M35.2, 
M35.8, M35.9) 
Primary systemic vasculitis: (ICD-9: 446.0, 446.2, 446.4, 446.5, 446.7, 447.6.   
ICD-10: D69.0, M31.0, M30.0, M31.3, M31.4, M31.5, M31.6, M31.7, M31.8, M31.9). 
 
Page 9 of 29
John Wiley & Sons, Inc.
Arthritis Care & Research
This article is protected by copyright. All rights reserved.
10 
 
Selected co-morbidities over the study period were expressed as a proportion of 
affected SLE cases and controls using the following ICD-9 and ICD-10 diagnostic 
codes:   
Cancer: all malignancies except lymphoma (ICD-9: 140-208, excluding 200-203. 
ICD-10: C00-D48, excluding C81-C85;  
Coronary heart disease (CHD) (ICD-9: 410-414. ICD-10: I20-I25) 
Cardiovascular disease excluding CHD (ICD-9: 390-459 excluding 410-414. ICD-10: 
I100-I99 excluding I20-I25) 
Diabetes (ICD-9: 250. ICD-10: E10-E14) 
Infection (ICD-9: 001-139, 465, 480-488. ICD-10: A00-B99, J06,J10-J18) 
Lymphoma (ICD-9: 200-203. ICD-10: C81-C85) 
Mental health (ICD-9: 290-319. ICD-10: F00-F99) 
Renal impairment (ICD-9: 580-589. ICD-10: N00-N19) 
 
Statistical analysis: The data were analyzed with SAS software v8.3 and SAS/Stat 
software 12.1 v9.3 (SAS Institute Inc., Cary N.C., USA). Descriptive statistics were used 
to characterize the prevalent SLE and control cohorts and variables included age, 
gender, number of ambulatory visits, number of emergency room visits, number of 
hospitalizations, and diagnosing physician groups. Censorship of data was addressed 
by using patient year exposures which was defined by each individual’s utilization or 
eligibility for utilization in  number of years between their incident diagnosis or matching 
and the last contact with the health service (i.e. physician contact, emergency room visit 
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and hospitalization). Linear regression and negative binomial models at the aggregate 
data level were run to examine differences in utilization between cases and controls and 
utilization over time. Models were also adjusted for the interaction of index year of 
utilization and case/control group. The log of patient year exposure was used as the 
offset in negative binomial models. The relationship between individual co-morbidities 
and case definition group was examined using the chi-square test for independence. 
The analysis was run separately for each case definition. 
Results 
Patients and controls: The number of SLE cases identified in the administrative 
datasets and available for study over the 13 years of observation varied with the 7 case 
definitions used (Table 1) (13). The definition with the greatest sensitivity was #1 (a 
single encounter with any physician) and the most specific definition was #5 
(hospitalization for which SLE was listed as one of the diagnostic codes). Using these 
two definitions the number of incident cases of SLE varied from 564 to 4,494 and the 
number of prevalent cases varied from 2,210 to 12,606 over the period of study. Cases 
had a comparable mean age and gender distribution regardless of the case definition 
for SLE (Table 1).  There was no significant difference between SLE cases and controls 
in the number of patient year exposures.  
 
Physician consultations: Starting from the index year (i.e. year of diagnosis of SLE in 
this incident cohort) the number of physician encounters per patient per year for cases 
and controls over the duration of followup is illustrated in Figure 1. SLE cases were 
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identified using the 7 case definitions for SLE. Utilization reflects the combination of 
outpatient ambulatory assessments and inpatient consultations by family physicians, 
general internists, rheumatologists and other physician groups. For all case definitions 
there was significantly higher utilization by SLE cases compared to controls. (p<0.001)  
In SLE cases the utilization was highest in the index year and fell thereafter. There was 
a significant fall in utilization by SLE cases over time (p<0.001) with all case definitions 
with the exception of case definition #1 (any physician encounter) For four SLE case 
definitions the utilization curves dipped substantially during the last 3 years of 
observation. The same observation occurred for the matched control group which 
suggests that the cause was unrelated to SLE. The gradual increase in utilization in the 
controls over time was most likely due to the change in health care needs with 
increasing age. 
 
The breakdown in physician encounters by specialty group and the change over time is 
illustrated in Figure 2 using SLE case definition #7 (Combination). For all case 
definitions the utilization of all physician groups was significantly higher for SLE cases 
than for their matched controls (P<0.01). This was apparent both at the initial encounter 
and over time. There was a significant fall in the utilization of all physician groups by 
SLE cases over time (p<0.01) with all case definitions. Subspecialty encounters was 
highest early in the disease course and by the fourth assessment the frequency fell by 
60% (Rheumatologists), 50% (Internal medicine) and 31% (other physicians). In 
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contrast, the frequency of visits to family physicians only fell by 9% over the same time 
and remained high for the duration of study. 
 
Emergency room visits: Utilization of the emergency room by SLE cases and controls 
is illustrated in Figure 3. Regardless of which case definition for SLE that was used, 
visits to the emergency room were significantly more frequent by SLE cases (P<0.001) 
which was most apparent early in the disease. There was a significant fall in emergency 
vists by SLE cases over time (p<0.001) with all case definitions.   
Hospitalizations: Hospital admission rates in SLE cases and controls are illustrated in 
Figure 4. For SLE cases, regardless of the definition, the hospital admission rate was 
significantly higher (P<0.001) compared to controls. This was especially true early in the 
disease course. There was a significant fall in hospitalizations for SLE cases over time 
(p<0.05) with case definitions #2 (McLean) and #5 (Hospitalization) but not with other 
case definitions. The dramatic spikes in hospital admissions seen among the cases and 
the controls most likely reflect random events among the relatively small numbers of 
cases and controls with at least 8-10 years of follow-up. Not surprisingly, patients 
identified through a hospital admission associated with SLE (case definition #5) had a 
high admission rate over time and the data point for the admission rate at the first 
encounter was so high (7.23) that it negated the ability to discriminate other 
hospitalization curves and was not included in the graph.  
Co-morbidities: The proportions of SLE patients and matched controls with selected 
co-morbidities over the period of study are summarized in Table 1.  Regardless of which 
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SLE case definition was used, all of the co-morbidities were more frequent in SLE cases 
compared to their matched controls (p<0.01).  Within SLE cases, patients identified 
through a hospital admission associated with SLE (case definition #5) had a higher 
proportion with co-morbidities. 
 
Discussion 
Health care utilization and associated costs have been studied in SLE and other chronic 
rheumatic diseases using different research methodologies. Most studies have involved 
secondary use of health administrative data on prevalent cohorts followed over short 
time frames. Some investigators have focused on disease subsets and demonstrated 
enhanced utilization and costs in association with specific manifestations (8)(11). In our 
study we wished to examine the change in health care utilization in the total population 
of SLE patients from the time of diagnosis over the ensuing years and to compare it to 
that seen in population controls. To this end we studied an incident cohort of SLE 
patients followed for up to 13 years using health administrative data which was 
previously validated against a clinical dataset. 
 
Studies of health care utilization have consistently found that it is higher in SLE patients 
than in comparator groups of patients (4, 5, 10, 16).  Utilization may be influenced by a 
variety of factors, including disease severity (17) (higher in lupus nephritis (8, 16) and 
neuropsychiatric lupus (11, 16)), race/ethnicity (lower in Hispanics (18)), and the type of 
the health care delivery (higher in fee for service system (3)). Previous studies have 
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been cross-sectional, retrospective and longitudinal in design, using prevalent rather 
than incident SLE cases and informed by observational data collected over 1 to 7 years. 
In the current study, utilization was assessed in the first year that the incident case 
occurred in the dataset which was taken as the year of diagnosis of SLE. Subsequent 
utilization was tracked for up to 13 years. Seven case definitions for SLE with a range of 
sensitivities and specificities were used in order to capture the full spectrum of SLE. The 
accuracy of these definitions and the identification of incident and prevalent cases of 
SLE have been published in detail elsewhere (13). Their use in this and future studies 
allows a form of sensitivity analyses for utilization and costs. The cases identified by 
each definition were matched by age and gender to 4 controls. The findings were 
remarkably consistent. Regardless of the SLE case definition, physician encounters 
were highest in the year of diagnosis, trending lower in subsequent years but always 
remained above that in matched controls.   
 
It is to be expected that multiple physician groups will be involved in the diagnosis and 
subsequent care of patients with SLE given the protean manifestations of the disease. 
In the current study, physician encounters were categorized into those with family 
physicians, general internists, rheumatologists and others. Utilization of all 4 physician 
groups was substantially higher in SLE cases compared to controls over the entire 
study. Encounters with family physicians, who are responsible for delivering primary 
care in the Canadian health care system, were the most frequent.  Subspecialty care 
was utilized most frequently early in the disease course, falling substantially over the 
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next 3 years. In contrast the frequency of encounters with family physicians changed 
relatively little over time. The interpretation and implications of these observations are 
two-fold. First, access to subspecialty care is most frequent and thus most critical 
around the time of diagnosis of SLE and in the first few years of followup when the 
disease is being stabilized. Second, the utilization of family physicians remains high but 
relatively constant over the course of the illness which underlines the important role that 
family physicians play in the long-term management of SLE patients. Given the need to 
prevent and treat comorbidities, which were universally more frequent in SLE patients 
compared to matched controls in our study, the strategic delivery of effective care will 
require ongoing co-ordination by rheumatologists and primary care physicians. 
 
The frequency of visits to hospital emergency rooms and admissions to hospital are 
indicators of the impact of a medical illness. Previous studies had demonstrated that 
both are higher in patients with SLE compared to controls (5, 10, 19, 20). The current 
study confirms this observation, but also demonstrates a consistent change in the 
pattern of utilization over the 13 years of observation. Utilization of both services was 
highest in the first year following the diagnosis of SLE (index year), and declined 
thereafter to eventually reach the same frequency as in controls by the end of the study.  
This may reflect a survivor effect due to excess mortality in SLE cases early in the 
disease course (21) that are thereby removed from the dataset. An alternative 
explanation is that following the diagnosis of SLE, appropriate treatment is initiated 
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leading to improved disease control and reduced need to visit the emergency room or 
require admission to hospital. 
 
There are a number of strengths to the current study. First, due to the Canada Health 
Act all patients accessed health care through a single provider, ensuring comprehensive 
data capture for all physician encounters, emergency room visits and hospitalizations. 
Second, the Nova Scotia population is stable with a mix of urban and rural communities 
and a range of socioeconomic groups and thus represents a general Canadian 
population. Third, the use of 7 validated case definitions reduces the risk of bias that 
could arise from using a more limited strategy for identifying cases and controls. 
 
There are also some limitations to the study. First, due to the homogenous nature of the 
Nova Scotia population it was not possible to examine the effect of race/ethnicity on 
health care utilization. Second, Athough the definition of incident cases was in 
agreement with traditional methodology in population health studies (12) it would not 
have excluded SLE patients with longstanding disease who relocated to Nova Scotia 
during the period of study.  Third, the range in the proportion of female patients between 
78.0% to 85.1% across case definitions is lower than the traditional 90% in most lupus 
cohorts, albeit that these are usually drawn from subspecialty clinics and inpatient units 
in health care facilities. Two recent population based studies revealed a gender 
distribution that was closer to our cohort. The Michigan Lupus Epidemiology and 
Surveillance program of incident SLE diagnosed by a rheumatologist reported a female 
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predominance of 85.4% in the total population and 83.5% in white patients (22). The 
Georgia Lupus Registry on incident SLE patients who fulfilled the ACR classification 
criteria (23) had a similar gender distribution with a female predominance of 85.4% in 
the total population and 85.5% in white patients. Fourth the cases were not stratified for 
disease activity or severity, in which utilization patterns may have been different. Finally, 
comparative data on patients with other chronic disease in a population of similar age 
and gender was not available. Future studies will address these deficiencies and 
determine the economic costs of health care utilization in this cohort of SLE patients. 
 
(Word count: Introduction to Discussion: 3,218) 
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Table 1: The proportion of SLE patients and matched controls with selected co-morbidities 
 
 
 
Any 
encounter 
MacLean MacLean 
Lacaille 
Shipton Rheumatologist Hospital Combination 
SLE N=3869 N=2075 N=1244 N=1860 N=1628 N=508 N=2559 
Mean age (years) 48.8 50.6 48.8 48.8 47.7 49.2 50.0 
Female (%) 78.0 81.8 82.9 81.2 85.1 81.4 81.1 
        
Comorbidity
*
        
Cancer  0.35 0.35 0.35 0.35 0.35 0.40 0.35 
CHD 0.28 0.29 0.29 0.29 0.27 0.42 0.30 
CVD 0.79 0.82 0.80 0.83 0.82 0.88 0.82 
Diabetes 0.19 0.18 0.18 0.18 0.19 0.24 0.19 
Infection 0.86 0.88 0.86 0.88 0.88 0.90 0.87 
Lymphoma 0.07 0.06 0.05 0.07 0.07 0.11 0.07 
Mental health 0.77 0.78 0.78 0.77 0.79 0.75 0.77 
Renal impairment 0.14 0.16 0.17 0.17 0.18 0.40 0.17 
        
Controls N=15476 N=8300 N=4976 N=7440 N=6512 N=2032 N=10236 
Cancer  0.20 0.20 0.21 0.20 0.19 0.19 0.20 
CHD 0.15 0.15 0.16 0.15 0.13 0.16 0.15 
CVD 0.51 0.51 0.52 0.51 0.48 0.51 0.51 
Diabetes 0.15 0.15 0.15 0.15 0.13 0.14 0.14 
Infection 0.55 0.54 0.55 0.55 0.55 0.56 0.55 
Lymphoma 0.02 0.02 0.02 0.02 0.02 0.01 0.02 
Mental health 0.52 0.52 0.52 0.52 0.52 0.53 0.52 
Renal  0.05 0.05 0.05 0.05 0.04 0.05 0.05 
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• Cancer: all malignancies except lymphoma; CHD: coronary heart disease; CVD: cardiovascular disease excluding 
CHD. 
Page 20 of 29
John Wiley & Sons, Inc.
Arthritis Care & Research
50
51
52
53
54
55
56
57
58
59
60
This article is protected by copyright. All rights reserved.
21 
 
      
Figure 1 
 
              
Page 21 of 29
John Wiley & Sons, Inc.
Arthritis Care & Research
50
51
52
53
54
55
56
57
58
59
60
This article is protected by copyright. All rights reserved.
22 
 
 Figure 2 
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Figure 3:     
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Figure 4: 
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Legends for figures: 
Figure 1: Total physician encounters in SLE patients (left panel) and controls (right 
panel) in the index year and over the following 13 years using 7 definitions for SLE to 
identify cases in administrative datasets. SLE cases were matched one to four by age 
and gender to a control cohort of patients who were enrolled in the same datasets but 
without a diagnosis of SLE or other connective tissue diseases. 
 
Figure 2: Physician encounters  by specialty group in SLE patients (left panel) in the 
index year and over 13 years of followup using case definition #7 (Combination) to 
identify SLE cases. These were matched one to four by age and gender to a control 
cohort of patients (right panel) who were enrolled in the same datasets but without a 
diagnosis of SLE or other connective tissue diseases. 
 
Figure 3: Utilization of the emergency room by SLE cases (left panel) and controls 
(right panel) in the index year and over the following 13 years using 7 definitions for SLE 
to identify cases in administrative datasets. SLE cases were matched one to four by age 
and gender to a control cohort of patients who were enrolled in the same datasets but 
without a diagnosis of SLE or other connective tissue diseases. 
 
Figure 4: Hospital admission rates in SLE cases (left panel) and controls (right panel) in 
the index year and over the following 13 years using 7 definitions for SLE to identify 
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cases in administrative datasets. SLE cases were matched one to four by age and 
gender to a control cohort of patients who were enrolled in the same datasets but 
without a diagnosis of SLE or other connective tissue diseases. For patients identified 
through a hospital admission associated with SLE (case definition #5) the data point for 
the admission rate at the first encounter was 7.23 and was not included in the graph 
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